We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisors Reject Expanded Indication for Amarin’s Heart Drug
FDA Advisors Reject Expanded Indication for Amarin’s Heart Drug
October 18, 2013
FDA advisors overwhelmingly recommended against approval of a new indication for Amarin’s flagship heart drug Vascepa, noting that results from an ongoing clinical trial are needed to determine if the indication is effective.